Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have received a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $8.50.

Several analysts have weighed in on the stock. Wall Street Zen upgraded shares of Gossamer Bio from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research report on Wednesday, October 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ciovacco Capital Management LLC acquired a new stake in Gossamer Bio in the third quarter worth $27,000. NorthCrest Asset Manangement LLC bought a new position in shares of Gossamer Bio during the fourth quarter worth about $36,000. Brighton Jones LLC bought a new position in shares of Gossamer Bio during the third quarter worth about $36,000. Brevan Howard Capital Management LP acquired a new stake in shares of Gossamer Bio in the 3rd quarter worth about $37,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Gossamer Bio in the 3rd quarter valued at about $41,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Trading Up 2.9%

Shares of NASDAQ:GOSS opened at $2.52 on Tuesday. The firm has a market cap of $583.28 million, a PE ratio of -3.65 and a beta of 1.92. The company has a fifty day simple moving average of $3.09 and a 200 day simple moving average of $2.55. Gossamer Bio has a 12-month low of $0.76 and a 12-month high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The company had revenue of $13.29 million for the quarter, compared to analyst estimates of $6.32 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%. As a group, equities research analysts forecast that Gossamer Bio will post -0.28 EPS for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.